Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Sagimet Biosciences Press Release
Media Coverage
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
Madrigal Pharmaceuticals Press Release
HistoIndex’s ML/AI solution to support VCU’s study of liver diseases
Medical Device Network
Sagimet embraces AI-driven pathology for more consistent NASH analysis
Clinical Trials Arena
Singapore: A Myriad of Biotech Financing Strategies
Precision diagnostics firm Histoindex began life as a spinoff from A*STAR and so received funding from the Singaporean government as well as from angel investors, corporations, and institutions. Co-founder and CEO, Dr. Gideon Ho, highlights Singapore’s advantages for innovative start-up firms looking to grow in Singapore.
A proprietary biophotonics technology and platform for stain-free AI-based digital pathology
Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.
HistoIndex Joins Consortium Developing Liver Disease Diagnostic Tool
GenomeWeb, 360Dx